MSF welcomes Indian government stand on certain aspects of strong EFTA trade deal
The Indian Commerce Ministry confirmed has rejected of Switzerland's demand for data exclusivity for medicines in the India-EFTA trade deal, and emphasised the importance of protecting the country’s generic drug production and supply.
Just a day earlier, Doctors Without Borders/Médecins Sans Frontières (MSF), Public Eye, and Delhi Network of Positive People issued a joint statement, highlighting their concerns about the damaging intellectual property (IP) provisions that were being negotiated in the India-EFTA trade deal that could negatively impact access to affordable medicines for millions of people in India and around the world.
One of the key concerns was the proposal to introduce an additional IP barrier, data exclusivity, as it would delay the registration of generic versions of new medicines or new formulations for a set period, even when there is no patent on the medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze